Navigation Links
Boston Scientific to Acquire BridgePoint Medical, Inc.

NATICK, Mass., Sept. 19, 2012 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) has signed a definitive agreement to acquire BridgePoint Medical, Inc., a privately held company based in Minneapolis, Minnesota.  BridgePoint Medical has developed a proprietary, catheter-based system to treat coronary chronic total occlusions (CTOs).  The transaction is expected to close in the fourth quarter of 2012 subject to customary closing conditions.

The BridgePoint Medical CTO system is comprised of the CrossBoss CTO Crossing Catheter and the Stingray® CTO Re-Entry System, and is designed to navigate highly diseased (occluded) coronary arteries as a means of blood flow restoration.  The system has received both U.S. Food and Drug Administration clearance and CE Mark, and is currently the only crossing and re-entry system cleared in the U.S. for use in coronary CTOs.

"The BridgePoint Medical CTO system is a compelling addition to our industry-leading suite of cardiology products," said Kevin Ballinger, president of the Interventional Cardiology Division at Boston Scientific.  "This acquisition strengthens our portfolio and demonstrates the Boston Scientific commitment to continued leadership in interventional cardiology."

CTOs are chronically occluded coronary arteries - typically for 3 months or longer - that prevent blood circulation to critical areas of the heart. CTO devices are designed to permit endovascular treatment in cases that otherwise might require a patient to undergo invasive intervention, such as coronary artery bypass surgery.

"Complete arterial blockages pose a major challenge in the treatment of coronary artery disease, and this CTO system gives physicians an important treatment option in these difficult cases," said Marty Leon, M.D., Director of the Center for Interventional Vascular Therapy at New York-Presbyterian Hospital/Columbia University Medical Center in New York City.  "Many of these patients would have previously been referred for bypass surgery, typically requiring weeks of recovery.  Now, many of them are able to go home within 24 hours."

"We look forward to welcoming the outstanding team at BridgePoint Medical to Boston Scientific," said Hank Kucheman, chief executive officer at Boston Scientific. "The acquisition of BridgePoint Medical is expected to build upon our rich product portfolio in cardiology and represents an important part of our growth strategy in this critical market.  We believe the BridgePoint coronary devices will provide the Boston Scientific Interventional Cardiology business a dedicated CTO solution while the Boston Scientific Peripheral Intervention business offers the TruePath CTO Device and OffRoad CTO Device.  This will position the company as the leader in CTO technologies across the cardiovascular system."

The transaction is expected to have an immaterial impact on GAAP and adjusted earnings in 2012 and 2013 and be modestly accretive thereafter.  Financial terms of the transaction are not being disclosed. 

The OffRoad CTO device is an investigational device and is not available for sale in the U.S.

About Boston Scientific

Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices that are used in a broad range of interventional medical specialties.  For more information, please visit:

About BridgePoint Medical

BridgePoint Medical, Inc. is a privately held company established in 2007 to design, develop and commercialize new technologies and techniques to treat challenging coronary artery disease. Investors include New Enterprise Associates, Polaris Venture Partners, Foundation Medical Partners and Michael Berman.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.  Forward-looking statements may be identified by words like "anticipate," "expect," "project," "believe," "plan," "estimate," "intend" and similar words.  These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance.  These forward-looking statements include, among other things, statements regarding our business plans and growth strategy, markets for our products and our position in those markets, timing of closing the transaction and expected accretion/dilution, and product performance and importance.  If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements.  These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release.  As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements. 

Factors that may cause such differences include, among other things: future economic, competitive, reimbursement and regulatory conditions; new product introductions; demographic trends; intellectual property; litigation; financial market conditions; and future business decisions made by us and our competitors.  All of these factors are difficult or impossible to predict accurately and many of them are beyond our control.  For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item 1A – Risk Factors in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which we may update in Part II, Item 1A – Risk Factors in Quarterly Reports on Form 10-Q we have filed or will file hereafter.  We disclaim any intention or obligation to publicly update or revise any forward-looking statements to reflect any change in our expectations or in events, conditions or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements.  This cautionary statement is applicable to all forward-looking statements contained in this document.

CONTACT:    Steven Campanini
                    508-652-5740 (office)
                    Media Relations
                    Boston Scientific Corporation

                    Michael Campbell
                    508-650-8023 (office)
                    Investor Relations
                    Boston Scientific Corporation

SOURCE Boston Scientific Corporation
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Medical Device Developers - Network at BIOMEDevice Boston Next Week
2. Boston Scientific Announces CE Mark and European Launch of Emerge™ PTCA Dilatation Catheter
3. Boston Scientific and Philips Healthcare Announce Collaboration to Enhance Imaging Equipment Offering
4. Boston Scientific Announces Positive Data From Lotus™ Transcatheter Aortic Valve Trial
5. One-Year EVOLVE Trial Clinical Results Confirm Comparable Safety And Effectiveness Data Of The Boston Scientific SYNERGY™ Stent Versus PROMUS Element™ Platinum Chromium Stent
6. Boston Scientific Announces FDA Approval and U.S. Launch of EPIC™ Vascular Stent
7. Boston Scientific Endoscopy Presents Promising Clinical Data During Digestive Disease Week ®
8. Clean Room Environmental Best Practices for Medical Device & Pharmaceutical Manufacturers are Focus of Boston Seminar on June 6
9. Boston Scientific Increases Longevity Projections for Its U.S. Defibrillators
10. Boston Scientific Closes Cameron Health Acquisition
11. Cumberland Pharmaceuticals To Present At The 2012 Wells Fargo Securities Healthcare Conference In Boston
Post Your Comments:
(Date:11/26/2015)... --> ... att använda SyMRI för att hitta optimal ... med multipel skleros (MS) eller hjärntumörmetastaser och ... för att kunna använda SyMRI Research Edition ... kan man generera flera konstrastbilder från en ...
(Date:11/26/2015)... 26, 2015 ... of the  "2016 Future Horizons and ... Drug Monitoring (TDM) Market: Supplier Shares, ... Opportunities"  report to their offering.  ... the addition of the  "2016 Future ...
(Date:11/26/2015)... , November 26, 2015 ... the "Self Administration of High Viscosity Drugs" ... ) has announced the addition of the ... report to their offering. --> Research ... addition of the "Self Administration of High ...
Breaking Medicine Technology:
(Date:11/27/2015)... ... November 27, 2015 , ... ... Microsoft Dynamics SL User Group (MSDSLUG). Recognized as Microsoft’s official group for end ... Microsoft Dynamics SL software users, partners, industry experts and representatives. Intellitec Solutions’ membership ...
(Date:11/27/2015)... (PRWEB) , ... November 27, 2015 , ... CBD ... Accreditation of Allied Health Education Programs (CAAHEP) awarded accreditation to its Diagnostic Medical Sonography ... CAAHEP accredited colleges, as only one of twelve colleges and universities in the state ...
(Date:11/27/2015)... ... 27, 2015 , ... Indosoft Inc., developer and distributor of ... 11 LTS (Long Term Support) into its Q-Suite 5.10 product line. , Making ... with a version of Asterisk that will receive not only security fixes, but ...
(Date:11/26/2015)... (PRWEB) , ... November 26, 2015 , ... ... American Express Travel Representative. As a franchise owner, Somu now offers travelers, value ... cruise, destination wedding packages, private cruise sales, as well as, cabin upgrades and ...
(Date:11/26/2015)... ... November 26, 2015 , ... WorldCare International, ... in the 61st annual Employee Benefits Conference. The Employee Benefits Conference was hosted ... 8th through Wednesday, November 11th, 2015. The conference was held at the Hawaii ...
Breaking Medicine News(10 mins):